



DOCKET NO: 200-019



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :
H. Kohler et al. :
Serial No: 10/652,864 : Art Unit: 1643
Filed: August 29, 2003 : Examiner: P. Tungaturthi
For: THERAPEUTIC APPLICATIONS OF : Confirmation No: 1487
NONCOVALENT DIMERIZING ANTIBODIES:

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In accordance with the provisions of 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is directed to the documents listed on the attached form PTO-1449B. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefor.

This Information Disclosure Statement is being filed within three months of the filing date for this application OR before

U.S. Serial No. 10/652,864


the mailing date of a first Office Action on the merits. No certification or fee is required.

Respectfully submitted,


James H. Meadows, Ph.D.
Reg. No. 33,965

Correspondence Address
Medicus Associates
2804 Kentucky Ave.
Joplin, MO 64804
Tel: 417-781-9965
Date: November 4, 2005

CERTIFICATE OF MAILING

I, James H. Meadows, hereby certify that this paper is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: *Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450* on the date November 4, 2005 Signature: 



Please type a plus sign (+) inside this box

+

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>			
		Application Number	10/652,864		
		Filing Date	August 29, 2003		
		First named Inventor	H. Kohler		
		Group Art Unit	1641		
		Examiner Name	P. Tungaturthi		
Sheet	1	of	2	Attorney Docket Number	200-019

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T6
		GHETIE, M., et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells," <u>PNAS USA</u> , (1997) 94: 7509-7514.	
		KANG, C-Y, et al. "Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide," <u>Science</u> , (1988) 240:1034-1036.	
		KANG, C-Y., et al., "Immunoglobulin with complementary paratope and idiotope," <u>J. Exp. Med.</u> (1986) 163: 787.	
		KAVERI, S., et al., "Antibodies of different specificities are self-binding: implication for antibody diversity," <u>Mol. Immunol.</u> , (1991) 2: 733-78.	
		KAVERI, S., et al., "Self-binding antibodies (autobodies) form specific complexes in solution," <u>J. Immunol.</u> (1990) 145: 2533-2538.	
		KOHLER, H., et al., "Superantibody activities: new players in innate and adaptive immune responses," <u>Immun. Today</u> , (1998) 19:221-227.	
		KOHLER, H., "Superantibodies: synergy of innate and acquired immunity," <u>Appl. Biochem. Biotechnol.</u> , (2000) 83: 1-9.	
		LIN, Y., et al., "Inhibition of nuclear translocation of transcription factor NF-kB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence," <u>J Biol Chem</u> , (1995) 270: 14255-14258.	
		MULLER, S., et al., "TransMabs: cell-penetrating antibodies, the next generation," <u>Expert Opin. Biol. Ther.</u> , (2005) 5: 237-241.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/652,864
				Filing Date	August 29, 2003
				First named Inventor	H. Kohler
				Group Art Unit	1641
				Examiner Name	P. Tungaturthi
Sheet	2	of	2	Attorney Docket Number	200-019

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T6
		ROJAS, M., et al., "Genetic engineering of proteins with cell membrane permeability," <u>Nat. Biotechnol.</u> , (1998) 16: 370-375.	
		ZHAO, Y., et al., "Chemical engineering of cell penetrating antibodies," <u>J. Immun. Methods</u> , (2001) 254: 137-145.	
		ZHAO, Y. et al., "Enhancing tumor targeting and apoptosis using noncovalent antibody homodimers," <u>J. Immunotherapy</u> , (2002) 25(5): 1-9.	
		ZHAO, Y., et al., "Enhanced Anti-B-cell Tumor Effects with Anti-CD20 Superantibody," <u>J. Immunotherapy</u> , (2002) 25: 57-62.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.